H.R. 8205 Passed both chambers Health

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

  1. Introduced
  2. Committee
  3. Passed House
  4. Passed Senate
  5. To President
  6. Became law
Sponsor Rep. Quigley, Mike [D-IL-5] Introduced April 6, 2026 Cosponsors 103 (39 R, 64 D) Latest action September 28, 2026

Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The bill reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. 
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Summary by the Congressional Research Service, Library of Congress.

Congress.gov

Actions

  1. Sep 28, 2026 Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  2. Jul 23, 2026 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  3. Jul 22, 2026 Motion to reconsider laid on the table Agreed to without objection.
  4. Jul 22, 2026 On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  5. Jul 22, 2026 Considered as unfinished business. (consideration: CR H5159)
  6. Jul 20, 2026 At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
  7. Jul 20, 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  8. Jul 20, 2026 Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  9. Jul 20, 2026 Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  10. Jul 9, 2026 Placed on the Union Calendar, Calendar No. 637.
  11. Jul 9, 2026 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  12. May 21, 2026 Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

Congressional and federal records come from official public sources: the House Clerk, the U.S. Senate, GovInfo and the Library of Congress (bill status), the Federal Register, and the congress-legislators project. They are copied on a schedule and may lag the official record by a few hours; the official sources govern. News and coverage counts are drawn from the 4Conservative index and reflect what the press published, not 4Conservative's views. Nothing here is an endorsement of any candidate, party or position. Terms of use.